Upgrade to SI Premium - Free Trial

Detailed Research: Economic Perspectives on Control4, REGENXBIO, Ferro, Kadmon, Hemispherx BioPharma, and Murphy Oil — What Drives Growth in Today's Competitive Landscape

October 18, 2018 9:20 AM

NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Control4 Corporation (NASDAQ: CTRL), REGENXBIO Inc. (NASDAQ: RGNX), Ferro Corporation (NYSE: FOE), Kadmon Holdings, Inc. (NYSE: KDMN), Hemispherx BioPharma, Inc. (NYSE: HEB), and Murphy Oil Corporation (NYSE: MUR), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CTRL DOWNLOAD: http://MarketSourceResearch.com/register/?so=CTRL RGNX DOWNLOAD: http://MarketSourceResearch.com/register/?so=RGNX FOE DOWNLOAD: http://MarketSourceResearch.com/register/?so=FOE KDMN DOWNLOAD: http://MarketSourceResearch.com/register/?so=KDMN HEB DOWNLOAD: http://MarketSourceResearch.com/register/?so=HEB MUR DOWNLOAD: http://MarketSourceResearch.com/register/?so=MUR

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Market Source Research, available for free download at the links above, examine Control4 Corporation (NASDAQ: CTRL), REGENXBIO Inc. (NASDAQ: RGNX), Ferro Corporation (NYSE: FOE), Kadmon Holdings, Inc. (NYSE: KDMN), Hemispherx BioPharma, Inc. (NYSE: HEB), and Murphy Oil Corporation (NYSE: MUR) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed October 16th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

CONTROL4 CORPORATION (CTRL) REPORT OVERVIEW

Control4's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Control4 reported revenue of $69.23MM vs $61.25MM (up 13.02%) and analysts estimated basic earnings per share $0.25 vs $0.15 (up 66.67%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Control4 reported revenue of $244.73MM vs $208.80MM (up 17.20%) and analysts estimated basic earnings per share $0.64 vs $0.55 (up 16.36%). Analysts expect earnings to be released on November 1st, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was $0.24. The estimated EPS forecast for the next fiscal year is $1.11 and is expected to report on February 14th, 2019.

To read the full Control4 Corporation (CTRL) report, download it here: http://MarketSourceResearch.com/register/?so=CTRL

-----------------------------------------

REGENXBIO INC. (RGNX) REPORT OVERVIEW

REGENXBIO's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, REGENXBIO reported revenue of $40.03MM vs $6.56MM (up 510.04%) and analysts estimated basic earnings per share $0.33 vs -$0.47. For the twelve months ended December 31st, 2017 vs December 31st, 2016, REGENXBIO reported revenue of $10.39MM vs $4.59MM (up 126.48%) and analysts estimated basic earnings per share -$2.45 vs -$2.38. Analysts expect earnings to be released on November 14th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was -$0.67. The estimated EPS forecast for the next fiscal year is -$4.07 and is expected to report on March 5th, 2019.

To read the full REGENXBIO Inc. (RGNX) report, download it here: http://MarketSourceResearch.com/register/?so=RGNX

-----------------------------------------

FERRO CORPORATION (FOE) REPORT OVERVIEW

Ferro's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Ferro reported revenue of $416.24MM vs $348.63MM (up 19.39%) and analysts estimated basic earnings per share $0.35 vs $0.25 (up 40.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Ferro reported revenue of $1,396.74MM vs $1,145.29MM (up 21.96%) and analysts estimated basic earnings per share $0.68 vs -$0.25. Analysts expect earnings to be released on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018. Reported EPS for the same quarter last year was $0.33. The estimated EPS forecast for the next fiscal year is $1.82 and is expected to report on February 27th, 2019.

To read the full Ferro Corporation (FOE) report, download it here: http://MarketSourceResearch.com/register/?so=FOE

-----------------------------------------

KADMON HOLDINGS, INC. (KDMN) REPORT OVERVIEW

Kadmon's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Kadmon reported revenue of $0.36MM vs $2.96MM (down 87.86%) and basic earnings per share $0.25 vs -$0.44. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Kadmon reported revenue of $12.26MM vs $26.06MM (down 52.93%) and analysts estimated basic earnings per share -$1.42 vs -$9.74. Analysts expect earnings to be released on November 8th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.42. The estimated EPS forecast for the next fiscal year is -$0.54 and is expected to report on March 5th, 2019.

To read the full Kadmon Holdings, Inc. (KDMN) report, download it here: http://MarketSourceResearch.com/register/?so=KDMN

-----------------------------------------

HEMISPHERX BIOPHARMA, INC. (HEB) REPORT OVERVIEW

Hemispherx BioPharma's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Hemispherx BioPharma reported revenue of $0.03MM vs $0.21MM (down 84.51%) and analysts estimated basic earnings per share -$0.05 vs -$0.08. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Hemispherx BioPharma reported revenue of $0.44MM vs $0.09MM (up 375.00%) and analysts estimated basic earnings per share -$0.29 vs -$0.34. Analysts expect earnings to be released on November 21st, 2018. The report will be for the fiscal period ending September 30th, 2018.

To read the full Hemispherx BioPharma, Inc. (HEB) report, download it here: http://MarketSourceResearch.com/register/?so=HEB

-----------------------------------------

MURPHY OIL CORPORATION (MUR) REPORT OVERVIEW

Murphy Oil's Recent Financial Performance

For the three months ended June 30th, 2018 vs June 30th, 2017, Murphy Oil reported revenue of $618.19MM vs $508.28MM (up 21.62%) and analysts estimated basic earnings per share $0.26 vs -$0.10. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Murphy Oil reported revenue of $2,225.13MM vs $1,811.24MM (up 22.85%) and analysts estimated basic earnings per share -$1.81 vs -$1.60. Analysts expect earnings to be released on November 7th, 2018. The report will be for the fiscal period ending September 30th, 2018. The reported EPS for the same quarter last year was -$0.03. The estimated EPS forecast for the next fiscal year is $2.15 and is expected to report on January 30th, 2019.

To read the full Murphy Oil Corporation (MUR) report, download it here: http://MarketSourceResearch.com/register/?so=MUR

-----------------------------------------

ABOUT MARKET SOURCE RESEARCH

Market Source Research delivers the key research reports that helps serious investors, registered brokers, professional traders, and personal investment advisers find reliable information in today's markets. Market Source Research's team is comprised of financial professionals, many of which hold Chartered Financial Analyst® (CFA®) designations and FINRA® BrokerCheck® certifications. Whether identifying emerging trends, or discovering new opportunity, the team at Market Source Research is dedicated to providing accurate, informative, and objective content that's ahead of the curve. With insights on individual companies as well as sectors, readers get the industry's best available combination of big-picture perspective as well as granular detail.

REGISTERED MEMBER STATUS

Market Source Research's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Market Source Research's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Market Source Research have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Market Source Research's Compliance department by Phone, at +1 (704) 343-6361, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Market Source Research, Market Source Research members, and/or Market Source Research affiliates are not responsible for any gains or losses that result from the opinions expressed. Market Source Research makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Market Source Research has not been compensated for the publication of this press release by any of the above mentioned companies. Market Source Research is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact: Hugo Moreau, Media Department Office: +1 (704) 343-6361 E-mail: [email protected]

© 2018 Market Source Research. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Source: Market Source Research

Categories

Press Releases